[HTML][HTML] Epidermal growth factor receptor (EGFR) in lung cancer: an overview and update
G Bethune, D Bethune, N Ridgway… - Journal of thoracic …, 2010 - ncbi.nlm.nih.gov
… This review provides an introduction to the role of EGFR in lung cancer … EGFR tyrosine
kinase inhibitors and the subsequent discovery of EGFR mutations in non-small cell lung cancers …
kinase inhibitors and the subsequent discovery of EGFR mutations in non-small cell lung cancers …
Mechanisms of resistance to EGFR tyrosine kinase inhibitors and therapeutic approaches: an update
A Ahsan - Lung Cancer and Personalized Medicine: Current …, 2016 - Springer
… (EGFR) is a receptor tyrosine kinase which belongs to the EGFR family, consisting of four
members: EGFR, … the tyrosine kinase activity of EGFR via homo- or heterodimerization with …
members: EGFR, … the tyrosine kinase activity of EGFR via homo- or heterodimerization with …
[HTML][HTML] Update on third-generation EGFR tyrosine kinase inhibitors
J Gray, E Haura - Translational Lung Cancer Research, 2014 - ncbi.nlm.nih.gov
… Among patients with non-small cell lung cancer (NSCLC), EGFR mutations, 90% of …
EGFR-tyrosine kinase inhibitor (TKI) therapies for EGFR-TKI-naïve NSCLC patients harboring EGFR …
EGFR-tyrosine kinase inhibitor (TKI) therapies for EGFR-TKI-naïve NSCLC patients harboring EGFR …
[HTML][HTML] Update of epidermal growth factor receptor-tyrosine kinase inhibitors in non-small-cell lung cancer
YM Chen - Journal of the Chinese medical Association, 2013 - Elsevier
… cancer (NSCLC). The availability of agents that target epidermal growth factor receptor (EGFR)-tyrosine …
In this report, we review the clinical data on the use of EGFR-tyrosine kinase …
In this report, we review the clinical data on the use of EGFR-tyrosine kinase …
Novel third-generation EGFR tyrosine kinase inhibitors and strategies to overcome therapeutic resistance in lung cancer
… of the successes in targeting oncogene addiction in cancer and the role of tumor-… tyrosine
kinase inhibitor, which was granted full FDA approval in March 2017 based on targeting EGFR …
kinase inhibitor, which was granted full FDA approval in March 2017 based on targeting EGFR …
Tyrosine kinase inhibitors for epidermal growth factor receptor gene mutation–positive non-small cell lung cancers: an update for recent advances in therapeutics
C Chung - Journal of Oncology Pharmacy Practice, 2016 - journals.sagepub.com
… adenocarcinoma and in smokers, are associated with resistance to EGFR tyrosine kinase
inhibitors (TKI). EGFR gene mutations are not found in tumors with K-RAS gene mutations. …
inhibitors (TKI). EGFR gene mutations are not found in tumors with K-RAS gene mutations. …
[HTML][HTML] Disease-free survival improved by use of adjuvant EGFR tyrosine kinase inhibitors in resectable non-small cell lung cancer: an updated meta-analysis
… (EGFR) tyrosine kinase inhibitors (TKIs) after surgery in patients with EGFR-mutant non-small
cell lung cancer (… previous one and presents our latest updates through the past few years. …
cell lung cancer (… previous one and presents our latest updates through the past few years. …
[HTML][HTML] Next-Generation EGFR Tyrosine Kinase Inhibitors for Treating EGFR-Mutant Lung Cancer beyond First Line
I Sullivan, D Planchard - Frontiers in medicine, 2017 - frontiersin.org
… EGFR TKIs, binding competitively and reversibly to the ATP-binding site of the EGFR
tyrosine … in outcome for NSCLC patients with activating EGFR mutations (L858R and Del19). …
tyrosine … in outcome for NSCLC patients with activating EGFR mutations (L858R and Del19). …
Current updates on EGFR and HER2 tyrosine kinase inhibitors for the breast cancer
PS Dhiwar, GSP Matada, NM Raghavendra… - Medicinal Chemistry …, 2022 - Springer
… Currently available EGFR/HER2 tyrosine kinase inhibitors (TKIs) exhibit many adverse …
of breast cancer and its therapy. It emphasizes the currently marketed drugs for EGFR, HER2, …
of breast cancer and its therapy. It emphasizes the currently marketed drugs for EGFR, HER2, …
Critical update and emerging trends in epidermal growth factor receptor targeting in cancer
J Baselga, CL Arteaga - Journal of Clinical Oncology, 2005 - ascopubs.org
… (EGFR) is a receptor tyrosine kinase of the ErbB receptor family that is abnormally activated
in many epithelial tumors. The aberrant activation of the EGFR … classes of anti-EGFR agents: …
in many epithelial tumors. The aberrant activation of the EGFR … classes of anti-EGFR agents: …
相关搜索
- egfr tyrosine kinase inhibitors
- egfr tyrosine non-small cell lung cancer
- egfr tkis cell lung cancer
- lung cancer egfr inhibitors
- common cancers anti-egfr therapy
- egfr tyrosine treatment options
- egfr mutant non-small cell lung cancer
- breast cancer tyrosine kinase inhibitors
- egfr mutant lung cancer
- egfr tkis non-small cell lung cancer
- egfr mutations cell lung cancer
- lung cancer tyrosine kinase inhibitors
- egfr mutations non-small cell lung cancer
- receptor tyrosine cell lung cancer
- receptor tyrosine non-small cell lung cancer
- egfr mutation receptor tyrosine kinase inhibitors